Figure 4.

Plasma cfDNA TOOs by methylation profiling

(A) Study design and analysis overview.

(B) Total cfDNA concentration and solid-organ-derived cfDNA concentration.

(C) cfDNA concentration derived from innate and adaptive immune cell types.

(D) Abundance of mitochondrial derived cfDNA.

(E) Correlation of cfDNA metrics with standard clinical measurements, along with the Pearson correlation Benjamini-Hochberg-adjusted p value for each comparison.

For (B) and (C), bars display significance comparisons between the group farthest to the right on the bar and all other groups. For (B)–(D), asterisks indicate statistical significance by Mann-Whitney U test using Benjamini-Hochberg-adjusted p values as follows: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.001. ASX, asymptomatic. See also Figure S5 and Tables S3 and S8.